Navigation Links
Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R)
Date:4/20/2009

an amendment to the submission once we have complete two-year data on the primary patient cohort," said Gary F. Burbach, president and chief executive officer of Thoratec.

In December 2008, Thoratec received approval from the FDA to end randomization in the trial, based on a pre-specified interim analysis of 67 percent of the first 200 patients that showed that patients implanted with the HeartMate II achieved statistically superior outcomes versus those in the control group who were implanted with the HeartMate XVE. Based on that analysis, the study's Data Safety Monitoring Board concurred with Thoratec's recommendation to eliminate randomization for patients enrolled in the trial under FDA-approved CAPs.

Patients in the trial were randomized to the HeartMate II or the HeartMate XVE -- currently the only device approved for DT -- on a 2-1 basis, respectively. The primary endpoint at two years is survival while remaining free from stroke and the need for reoperation for pump repair or replacement. Secondary endpoints included adverse events, functional status, hospitalization, assessment of neuro-cognitive function and patient quality of life.

"The data from the trial demonstrate that the HeartMate II is superior to the XVE, based on device performance and the primary patient outcome of two-year survival free from stroke and reoperation for device replacement. The data also showed that key adverse events, such as infection, sepsis and right heart failure, were significantly lower for the HeartMate II versus the XVE. As a result, this submission seeking FDA approval for Destination Therapy is an important milestone in Thoratec's mission to bring breakthrough therapies and new hope to the thousands of patients and their families suffering from advanced heart failure, as well as the clinicians who work tirelessly to treat them," Burbach said.

"The commercial experience of the HeartMate II for BTT
'/>"/>

SOURCE Thoratec Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
2. Thoratec Presentation at Bear Stearns Conference To Be Webcast
3. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
4. Thoratec Presentation at JP Morgan Conference to be Webcast
5. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
6. Thoratec Schedules Third Quarter 2008 Conference Call, Webcast
7. Thoratec Reports 44 Percent Increase in Third Quarter Revenues
8. Thoratec Presentation at J.P. Morgan Conference to be Webcast
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015  Johnson & Johnson Innovation ... South San Francisco (JLABS @SSF), a 30,000-square ... South San Francisco, Calif. The Johnson ... to 50 startups from across the healthcare spectrum including ... The first resident startups have been selected, ...
(Date:3/3/2015)... 2015  Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer ... focus on protecting the microbiome, announced today that Jeffrey ... the 27th Annual ROTH Conference being held on March 8-11, ... in Dana Point, CA. Mr. Riley ... 1:00 p.m. (Pacific Time). A live webcast of ...
(Date:3/3/2015)... March 03, 2015 GlobalStemCellsGroup.com ... faculty. Camacho Alcocer, a biomedical researcher and founding partner ... join GSCG’s team of biomedical professors who will teach ... , Criogenix SA de CV is a private company ... Institutions and Companies in Mexico (RENIECYT). , Camacho Alcocer ...
(Date:3/2/2015)... Md. (PRWEB) March 02, 2015 Shimadzu ... sessions and present on LCMS and marijuana analysis at ... place March 8 to 12 at the Ernest N. ... Attendees can stop by booth 3121 to discuss laboratory ... the company’s innovative, proven products help save time, money ...
Breaking Biology Technology:Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5Synthetic Biologics to Present at the 27th Annual ROTH Conference 2Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 2Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 3Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 2Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 3
... and MONTREAL, Dec. 9 /PRNewswire-FirstCall/ - ProMetic Life ... subsidiary, ProMetic BioSciences Ltd ("PBL"), has signed a ... European Biopharmaceutical company estimated to be worth up ... with first shipment delivery starting this quarter. This ...
... KNDL ) a,leading, global full-service clinical research organization, ... Raymond James,Boston Fall Investors Conference. The conference will be ... in Boston on Dec. 11, 2008. Kendle,s,presentation is scheduled ... (Logo: ...
... Nile Therapeutics, Inc. (Nasdaq: NLTX ), today announced preliminary ... of CD-NP, a novel chimeric natriuretic peptide, in patients with heart failure. ... , , ... Blood pressure effects were dose dependent ...
Cached Biology Technology:ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company 2ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company 3Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference 2Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure 2Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure 3Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure 4Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure 5
(Date:2/5/2015)... 26, 2015   Epic Sciences , a precision diagnostics ... that Murali Prahalad , Ph.D., president and CEO, is ... (PMWC) 2015: Silicon Valley, which is taking place at ... on January 26-28, 2015. Dr. ... as Biomarkers." Last year, Epic Sciences was a finalist in ...
(Date:2/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ) ... Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, ... their offering. , In global ... anticipated to overtake North America ... towards IT security, government biometric based projects such ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... surface of the earth, an influential community of microbes ... of those communities, scientists have now catalogued and compared ... the roots of the model plant Arabidopsis ... for examining how plants interact with a microbial community ...
... N.Y. -- In a curious evolutionary twist, several species of ... material from a virus into their genomes, according to new ... that several types of fruit fly -- scientific name ... for the sigma virus, a fly virus in the same ...
... MA -- The wrinkles on a raisin result from a ... stiff and buckles to accommodate its shrinking size. Now, a ... harness that same principle in a controlled and orderly way, ... basic method, they say, could be harnessed for a wide ...
Cached Biology News:Roots and microbes: Bringing a complex underground ecology into the lab 2Roots and microbes: Bringing a complex underground ecology into the lab 3Roots and microbes: Bringing a complex underground ecology into the lab 4Roots and microbes: Bringing a complex underground ecology into the lab 5In fly DNA, the footprint of a fly virus 2In fly DNA, the footprint of a fly virus 3Wrinkled surfaces could have widespread applications 2Wrinkled surfaces could have widespread applications 3
... are designed for enhanced translation of cloned sequences ... reticulocyte lysate. The maps for pCITE-2b(+) and pCITE-2c(+) ... exceptions: pCITE-2b(+) is a 3793 bp plasmid; it ... Xcm I sites. Subtract 7 bp from all ...
...
...
...
Biology Products: